CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 1973; 23:74-80
doi: 10.3322/canjclin.23.2.74
© 1973 American Cancer Society
This Article
Right arrow Full Text (PDF) Freely available
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcove, R. C.
Right arrow Articles by Levin, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marcove, R. C.
Right arrow Articles by Levin, A. G.

CA: A Cancer Journal for Clinicians, Vol 23, 74-80, Copyright © 1973 by American Cancer Society

Vaccine Trials for Osteogenic Sarcoma

A Preliminary Report

Ralph C. Marcove M.D.1, Valerie Miké Ph.D.2, Andrew G. Huvos M.D.3, Chester M. Southam M.D.4, and Arthur G. Levin M.B., Ch.B.5

1 Chief of Bone Tumor Service and Associate Attending Physician, Hospital for Special Surgery; Associate Attending Physician, Bone Service, Memorial Hospital for Cancer and Allied Diseases, New York, New York.
2 Assistant Professor of Biostatistics, Memorial Hospital for Cancer and Allied Diseases,
3 Assistant Attending Pathologist, Memorial Hospital for Cancer and Allied Diseases.
4 Professor of Medicine and Head, Division of Medical Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania.
5 Nairobi Regional Centre, Nairobia, Kenya.

Twenty-one patients with osteogenic sarcoma of the long bones treated by a lysed cell vaccine, in addition to routine amputation, appear to have an encouraging response to vaccine treatment, compared with both the whole cell vaccine and the control series. (See Figure below.)

In view of the infrequency of follow-up chest films in the control group, an inherent bias is present in our data, making the time to metastasis for control patients appear longer. In addition, all patients in the control group have been followed well over two years, whereas only six of the nine disease-free patients in the lysed cell series have had long-term follow-up. Therefore, this paper is intended as a preliminary report only. There is, however, a statistically significant difference between the response rates of the two vaccine groups which suggests clinical evidence of immunologic manipulation of a human tumor.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1973 by American Cancer Society.